Worldwide Medicinal Chemistry, Pfizer PharmaTherapeutics Research and Development, Cambridge, Massachusetts, USA.
Cardiovascular and Metabolic Diseases Research Unit, Pfizer PharmaTherapeutics Research and Development, Cambridge, Massachusetts, USA.
Nat Chem Biol. 2014 Aug;10(8):629-31. doi: 10.1038/nchembio.1581. Epub 2014 Jul 6.
We report that 4-(3-(benzyloxy)phenyl)-2-ethylsulfinyl-6-(trifluoromethyl)pyrimidine (BETP), which behaves as a positive allosteric modulator at the glucagon-like peptide-1 receptor (GLP-1R), covalently modifies cysteines 347 and 438 in GLP-1R. C347, located in intracellular loop 3 of GLP-1R, is critical to the activity of BETP and a structurally distinct GLP-1R ago-allosteric modulator, N-(tert-butyl)-6,7-dichloro-3-(methylsulfonyl)quinoxalin-2-amine. We further show that substitution of cysteine for phenylalanine 345 in the glucagon receptor is sufficient to confer sensitivity to BETP.
我们报告称,4-(3-(苄氧基)苯基)-2-乙基亚磺酰基-6-(三氟甲基)嘧啶(BETP)作为胰高血糖素样肽-1 受体(GLP-1R)的正变构调节剂,可使 GLP-1R 中的半胱氨酸 347 和 438 发生共价修饰。GLP-1R 中的细胞内环 3 中的 C347 对于 BETP 和结构不同的 GLP-1R 前体变构调节剂 N-(叔丁基)-6,7-二氯-3-(甲基磺酰基)喹喔啉-2-胺的活性至关重要。我们进一步表明,将胰高血糖素受体中的苯丙氨酸 345 替换为半胱氨酸足以使 BETP 敏感。